Tags

Type your tag names separated by a space and hit enter

A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US.
J Asthma Allergy. 2016; 9:135-43.JA

Abstract

A novel intranasal formulation of azelastine HCl (AZE, an antihistamine) and fluticasone propionate (FP, a corticosteroid) in a single spray (MP-AzeFlu [Dymista®]) was studied in four randomized, double-blind, placebo-controlled trials of patients with seasonal allergic rhinitis conducted in the US. Study sites were distributed so that all major US geographic regions and the prevalent pollens within these regions were represented. Spring and summer studies included patients aged 12 years and older with allergy to grass and tree pollens. Fall studies enrolled patients with allergy to weeds, in particular ragweed. In addition, a study was conducted during the winter months in patients with allergy to mountain cedar pollen in TX, USA. Regardless of allergy season or prevalent pollen, MP-AzeFlu improved nasal symptoms of allergic rhinitis (AR) to a significantly greater degree than AZE or FP, two treatments that currently are recommended as the first-line AR therapy. MP-AzeFlu improved all individual AR symptoms and was significantly better than FP and AZE for nasal congestion relief, which is generally accepted as the most bothersome symptom for AR patients. The onset of action was within 30 minutes. MP-AzeFlu also provided clinically important improvement in the overall Rhinoconjunctivitis Quality of Life Questionnaire score and significantly improved ocular symptoms of rhinitis compared to placebo. Favorable characteristics of the MP-AzeFlu formulation as well as superior clinical efficacy make it an ideal intranasal therapy for AR.

Authors+Show Affiliations

Allergy Associates Medical Group, Inc., San Diego, CA, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27468241

Citation

Prenner, Bruce M.. "A Review of the Clinical Efficacy and Safety of MP-AzeFlu, a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, in Clinical Studies Conducted During Different Allergy Seasons in the US." Journal of Asthma and Allergy, vol. 9, 2016, pp. 135-43.
Prenner BM. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. J Asthma Allergy. 2016;9:135-43.
Prenner, B. M. (2016). A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. Journal of Asthma and Allergy, 9, 135-43. https://doi.org/10.2147/JAA.S98172
Prenner BM. A Review of the Clinical Efficacy and Safety of MP-AzeFlu, a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, in Clinical Studies Conducted During Different Allergy Seasons in the US. J Asthma Allergy. 2016;9:135-43. PubMed PMID: 27468241.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. A1 - Prenner,Bruce M, Y1 - 2016/07/11/ PY - 2016/7/29/entrez PY - 2016/7/29/pubmed PY - 2016/7/29/medline KW - Dymista KW - Texas mountain cedar KW - grass pollen KW - intranasal therapy KW - ragweed KW - seasonal allergic rhinitis SP - 135 EP - 43 JF - Journal of asthma and allergy JO - J Asthma Allergy VL - 9 N2 - A novel intranasal formulation of azelastine HCl (AZE, an antihistamine) and fluticasone propionate (FP, a corticosteroid) in a single spray (MP-AzeFlu [Dymista®]) was studied in four randomized, double-blind, placebo-controlled trials of patients with seasonal allergic rhinitis conducted in the US. Study sites were distributed so that all major US geographic regions and the prevalent pollens within these regions were represented. Spring and summer studies included patients aged 12 years and older with allergy to grass and tree pollens. Fall studies enrolled patients with allergy to weeds, in particular ragweed. In addition, a study was conducted during the winter months in patients with allergy to mountain cedar pollen in TX, USA. Regardless of allergy season or prevalent pollen, MP-AzeFlu improved nasal symptoms of allergic rhinitis (AR) to a significantly greater degree than AZE or FP, two treatments that currently are recommended as the first-line AR therapy. MP-AzeFlu improved all individual AR symptoms and was significantly better than FP and AZE for nasal congestion relief, which is generally accepted as the most bothersome symptom for AR patients. The onset of action was within 30 minutes. MP-AzeFlu also provided clinically important improvement in the overall Rhinoconjunctivitis Quality of Life Questionnaire score and significantly improved ocular symptoms of rhinitis compared to placebo. Favorable characteristics of the MP-AzeFlu formulation as well as superior clinical efficacy make it an ideal intranasal therapy for AR. SN - 1178-6965 UR - https://www.unboundmedicine.com/medline/citation/27468241/A_review_of_the_clinical_efficacy_and_safety_of_MP_AzeFlu_a_novel_intranasal_formulation_of_azelastine_hydrochloride_and_fluticasone_propionate_in_clinical_studies_conducted_during_different_allergy_seasons_in_the_US_ L2 - https://dx.doi.org/10.2147/JAA.S98172 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.